Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Company Research
Source: GlobeNewswire
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the issuance of U.S. Patent No. 12,077,515, titled “Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease.” This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma’s intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes. The newly issued patent covers a series of selective HDAC inhibitors designed to modulate the expression of genes involved in cancer progression, immune responses, and other critical biological pathways. These inhibitors are being developed as potential treatments for a range of human diseases, including cancer. Shuttle Pharma’s primary purpose is to develop and commercialize
Show less
Read more
Impact Snapshot
Event Time:
SHPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SHPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SHPH alerts
High impacting Shuttle Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SHPH
News
- Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaGlobeNewswire
- Shuttle Pharma Provides Second Quarter 2024 Corporate UpdateGlobeNewswire
- Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
- Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) [Yahoo! Finance]Yahoo! Finance
- Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)GlobeNewswire
SHPH
Sec Filings
- 9/20/24 - Form S-1
- 9/16/24 - Form 424B3
- 9/13/24 - Form 8-K
- SHPH's page on the SEC website